Related Experiment Video

Updated: Jun 27, 2025

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

11.7K

Applied Cardio-Oncology in Hematological Malignancies: A Narrative Review

Evdokia Mandala1, Kyranna Lafara1, Dimitrios Kokkinovasilis1

  • 1Division of Hematology, Forth Department of Medicine, School of Medicine, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece.

Life (Basel, Switzerland)
|April 27, 2024
PubMed

Insights

Cardio-oncology manages heart issues in blood cancer patients. This review details therapy-related heart damage, risk, and detection methods for leukemia, lymphoma, and myeloma.

Area of Science:

  • Cardio-oncology
  • Hematology
  • Cardiovascular Medicine

Background:

  • Cardio-oncology integrates cardiovascular care for hematological malignancy patients.
  • Therapy-related cardiotoxicity is a significant concern in treating blood cancers like leukemia, lymphoma, and multiple myeloma.

Purpose of the Study:

  • To provide a comprehensive overview of cardiotoxicity in hematological malignancies.
  • To detail the definition, risk stratification, and diagnostic approaches for therapy-related cardiac dysfunction.

Main Methods:

  • Narrative review of current literature on cardiotoxicity in hematological cancers.
  • Focus on multimodality imaging and cardiac biomarkers for early detection.
  • Analysis of cardiotoxic profiles associated with various cancer therapies.

Main Results:

  • Cardiotoxicity is a common complication of diverse hematological cancer treatments, including chemotherapy, immunotherapy, and stem cell transplantation.
  • Early detection of myocardial dysfunction and electrical instability is crucial.
  • Specific therapeutic agents and interventions carry distinct cardiotoxic risks.

Conclusions:

  • Effective management of cardiotoxicity is essential for improving outcomes in patients with hematological malignancies.
  • Multimodality imaging and biomarkers aid in risk stratification and monitoring.
  • Understanding drug-specific cardiotoxicity profiles informs clinical practice and patient care.

Keywords:
cardio-oncologycardiotoxicityhematological malignanciesmultimodality imagingmyocardial dysfunction

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

327
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.9K

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.8K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K